EyePoint Pharmaceuticals Inc at HC Wainwright Ophthalmology Virtual Conference - Panel Discussion Transcript
Good morning, and thank you for joining the H.C. Wainwright's 3rd Annual Ophthalmology Virtual Conference. This is a panel discussion on sustained treatment for wet AMD. My name is Yi Chen, and I'm a healthcare research analyst at H.C. Wainwright.
Today, we have the pleasure of having Dr. Thomas Ciulla, Chief Medical Advisor, Retina and Chair of Scientific Advisory Board at Clearside Biomedical; and Dr. Jay Duker, President and CEO of EyePoint Pharmaceuticals; and Mr. Antony Mattessich, President and CEO of Ocular Therapeutix join us in this session. We also have the privilege of having Dr. Thanos Papakostas from Retina Institute join us as a key panelist. Welcome to the panel.
Questions & Answers
Dr. Papakostas, could you please give us a brief introduction of yourself and your practice? And more specifically, could you give us an overview of the current treatment paradigm for wet AMD in your practice?
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |